Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

7.18
Delayed Data
As of Aug 26
 +0.31 / +4.51%
Today’s Change
4.08
Today|||52-Week Range
11.73
-14.42%
Year-to-Date
Better Buy: Novavax, Inc. vs. Inovio Pharmaceuticals
Aug 15 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close6.87
Today’s open7.20
Day’s range7.04 - 7.29
Volume5,417,793
Average volume (3 months)5,047,130
Market cap$1.9B
Dividend yield--
Data as of 3:59pm ET, 08/26/2016

Growth & Valuation

Earnings growth (last year)-62.16%
Earnings growth (this year)-78.49%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+18.24%
P/E ratioNM
Price/Sales60.70
Price/Book6.62

Competitors

 Today’s
change
Today’s
% change
ARIAARIAD Pharmaceutical...+0.05+0.49%
BLUEbluebird bio Inc+1.26+2.52%
OPHTOphthotech Corp+1.02+1.95%
EXASExact Sciences Corp+0.14+0.73%
Data as of 3:59pm ET, 08/26/2016

Financials

Next reporting dateNovember 2, 2016
EPS forecast (this quarter)-$0.25
Annual revenue (last year)$36.3M
Annual profit (last year)-$156.9M
Net profit margin-432.93%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stanley C. Erck
Senior Vice President-
Quality Operations
Robert Darius
Corporate headquarters
Gaithersburg, Maryland

Forecasts

Partner Offers

Search for Jobs